Overview of EMA recommendations

COVID-19 Vaccines and Treatments

Overview of COVID-19 vaccination in the European Union

Vaccines authorised for use in the EU
- Comirnaty (BioNTech and Pfizer)
- Spikevax (Moderna)
- Vaxzevria (AstraZeneca)
- COVID-19 Vaccine Janssen
- Nuvaxovid (Novavax)

Vaccines under evaluation
- GamCOVID-Vac (Gamaleya Institute)
- COVID-19 Vaccine (Zhejiang)
- Sputnik V, Gam-COVID-Vak (Gamaleya Institute)
- COVID-19 Vaccine (Vero Cell)

Treatments authorised for use in the EU
- Remdesivir (Vieche Therapeutics / Raviglione)
- Baricitinib (Eli Lilly & Co.)
- Anakinra (Kineret)

Treatments under evaluation
- Tixagevimab / Cilgavimab (Evusheld)
- Evonik/Remdesivir (Belay)
- Molnupiravir (Lagevrio)
- Baricitinib (Olumiant)

One year since the first COVID-19 vaccine approval in the EU

COVID-19 vaccination in the European Union

78.4% of the EU adult population fully vaccinated

1.074 billion doses delivered.

As of 21 December 2021
Source: European Commission (as of 17 December 2021)

COVID-19 Vaccines

COVID-19 Treatments

COVID-19 Vaccines

COVID-19 Treatments

Overview of COVID-19 vaccination in the European Union

Vaccines authorised for use in the EU
- Comirnaty (BioNTech and Pfizer)
- Spikevax (Moderna)
- Vaxzevria (AstraZeneca)
- COVID-19 Vaccine Janssen
- Nuvaxovid (Novavax)

Vaccines under evaluation
- GamCOVID-Vac (Gamaleya Institute)
- COVID-19 Vaccine (Zhejiang)
- Sputnik V, Gam-COVID-Vak (Gamaleya Institute)
- COVID-19 Vaccine (Vero Cell)

Treatments authorised for use in the EU
- Remdesivir (Vieche Therapeutics / Raviglione)
- Baricitinib (Eli Lilly & Co.)
- Anakinra (Kineret)

Treatments under evaluation
- Tixagevimab / Cilgavimab (Evusheld)
- Evonik/Remdesivir (Belay)
- Molnupiravir (Lagevrio)
- Baricitinib (Olumiant)

One year since the first COVID-19 vaccine approval in the EU

COVID-19 vaccination in the European Union

78.4% of the EU adult population fully vaccinated

1.074 billion doses delivered.

As of 21 December 2021
Source: European Commission (as of 17 December 2021)